Heartworm Disease: How It Damages the Heart and How to Prevent It

Heartworm disease is one of the most devastating parasitic conditions affecting companion animals, caused by the filarial nematode Dirofilaria immitis. Unlike most intestinal parasites that remain confined to the gastrointestinal tract, adult heartworms take up residence in the pulmonary arteries and, in severe infestations, the right side of the heart itself — growing up to 30 centimetres in length and living for five to seven years in dogs. The disease is transmitted exclusively through the bite of an infected mosquito, making it impossible for pets to contract heartworm directly from one another. More than 70 species of mosquito are capable of transmitting Dirofilaria immitis, and the disease has been documented on every continent except Antarctica, with endemic regions spanning the Americas, southern Europe, Asia, and Australia.

"Heartworm disease is entirely preventable, yet it remains one of the most common causes of acquired heart and lung disease in dogs across endemic regions. The tragedy of every heartworm case I treat is that it could have been avoided with a simple, inexpensive monthly preventive. By the time clinical signs appear, significant and often irreversible cardiovascular damage has already occurred." — Dr. Sarah Chen, DVM

The lifecycle of Dirofilaria immitis is complex and requires both a mosquito intermediate host and a mammalian definitive host to complete. When a mosquito feeds on an infected animal, it ingests microscopic larval heartworms called microfilariae (L1 stage) circulating in the bloodstream. Over the next 10 to 14 days — depending on environmental temperature — these microfilariae develop through two moults within the mosquito (L1 to L2 to L3), reaching the infective third larval stage. When the mosquito takes its next blood meal, infective L3 larvae are deposited on the skin surface and enter through the bite wound. Once inside the new host, the larvae migrate through subcutaneous tissue and muscle over the next several months, moulting twice more (L3 to L4 to L5/immature adult) before reaching the pulmonary arteries approximately 70 to 90 days post-infection. The worms continue to mature over the next three to four months, reaching full adult size and reproductive capability approximately six months after the initial mosquito bite.

Understanding this lifecycle is critical because it explains several important features of the disease: the long lag between infection and clinical signs, why testing cannot detect infection until at least five to six months post-exposure, and why prevention works by targeting the early larval stages before they reach the heart. For a broader overview of how parasites affect pet health, see our guide on common parasites in dogs and cats.

The cardiovascular damage caused by heartworm disease is progressive, cumulative, and in many cases irreversible — even after successful treatment to kill the adult worms. Understanding the specific mechanisms of damage helps explain why prevention is so vastly superior to treatment and why early detection matters enormously for treatment outcomes.

Pulmonary arterial damage is the earliest and most significant pathological change. Adult heartworms reside primarily in the pulmonary arteries — the large blood vessels carrying deoxygenated blood from the right ventricle to the lungs. The physical presence of worms within these vessels causes chronic endothelial damage (injury to the inner lining of the blood vessels), triggering an intense inflammatory response. The body attempts to repair this damage through a process called villous proliferation — the growth of finger-like projections of tissue along the vessel walls — which paradoxically narrows the vessel lumen and increases resistance to blood flow. Over time, the pulmonary arteries become thickened, tortuous, and increasingly rigid, losing their normal ability to accommodate changes in blood flow during exercise.

As the pulmonary arteries become increasingly obstructed and stiffened, the right ventricle of the heart must work progressively harder to pump blood through the lungs. This increased workload leads to right-sided cardiac hypertrophy — the muscular wall of the right ventricle thickens as it compensates for the increased resistance. While this compensation maintains adequate blood flow initially, the right ventricle has anatomical limits to how much it can hypertrophy. Eventually, the muscle can no longer compensate, and the right ventricle begins to dilate and fail — a condition known as cor pulmonale, or right-sided congestive heart failure. When this occurs, blood backs up into the systemic venous circulation, causing jugular vein distension, liver congestion (hepatomegaly), and fluid accumulation in the abdomen (ascites).

In severe infestations involving large numbers of worms (50 or more in a large dog, or as few as one to two in a cat), worms may physically obstruct the tricuspid valve or extend from the pulmonary arteries back into the right atrium and even the caudal vena cava. This catastrophic situation — known as caval syndrome — causes acute, life-threatening cardiovascular collapse with profound haemolytic anaemia (destruction of red blood cells as they are sheared passing through masses of worms), disseminated intravascular coagulation (DIC), multi-organ failure, and death within 24 to 48 hours if the worms are not physically removed through emergency surgery (worm extraction via jugular venotomy). Caval syndrome represents the most extreme and dramatic manifestation of heartworm disease, but even dogs with moderate infections suffer significant, lasting damage to their pulmonary vasculature.

An often-overlooked aspect of heartworm pathology is the damage that occurs when adult worms die — whether naturally at the end of their lifespan, or as a result of adulticide treatment. Dead and dying worms fragment and are carried downstream into smaller pulmonary arterial branches, causing acute thromboembolism (blood vessel blockage). The resulting inflammation, blood clot formation, and tissue death in the lungs can cause severe respiratory distress, coughing, haemoptysis (coughing up blood), and in some cases fatal pulmonary thromboembolism. This is precisely why the treatment protocol for heartworm disease includes strict exercise restriction — physical activity increases cardiac output and blood flow through the lungs, increasing the risk of dead worm fragments causing massive thromboembolism.

While dogs are the natural definitive host for Dirofilaria immitis and harbour the disease most commonly, cats can also be infected — and heartworm disease in cats presents a fundamentally different and in many ways more dangerous clinical picture than in dogs. Understanding these species differences is essential for appropriate prevention, diagnosis, and management.

In dogs, heartworm is a well-characterised progressive disease. Dogs are highly susceptible hosts — virtually all infective larvae deposited by mosquitoes will successfully develop into adult worms, and without treatment, worm burdens can reach into the hundreds in heavily exposed dogs. Adult worms live five to seven years in dogs, and infected dogs with circulating microfilariae serve as reservoirs, perpetuating the transmission cycle within a community. The clinical presentation in dogs follows a predictable progression: early infections are often asymptomatic, progressing to exercise intolerance and mild cough as pulmonary arterial disease develops, then to moderate-to-severe cough, lethargy, and weight loss as the disease advances, and finally to right-sided heart failure with ascites in advanced cases. Diagnosis in dogs is relatively straightforward using antigen tests that detect proteins secreted by adult female worms, with sensitivity exceeding 99 per cent for infections involving at least one mature female.

In cats, heartworm disease is profoundly different. Cats are aberrant, resistant hosts — their immune system mounts a vigorous response against the developing larvae, and most larvae are killed before reaching adulthood. When worms do survive to adulthood, the typical burden is only one to three worms, compared to dozens or hundreds in dogs. However, this small worm burden does not mean the disease is less dangerous — in fact, the opposite may be true. Even a single worm in a cat can cause severe, life-threatening disease because the feline pulmonary vasculature is much smaller than the canine system. Furthermore, cats suffer from a syndrome unique to their species called heartworm-associated respiratory disease (HARD), which occurs when immature worms arrive in the pulmonary arteries and die — the resulting inflammatory response causes asthma-like signs (coughing, wheezing, respiratory distress) that may be misdiagnosed as feline asthma or bronchitis.

Diagnosis of heartworm in cats is far more challenging than in dogs. Antigen tests have poor sensitivity in cats because the worm burden is typically low (often only male worms, which are not detected by antigen tests that target female-specific proteins). Antibody tests can detect exposure but do not confirm active infection. Echocardiography may visualise worms in the pulmonary arteries, but requires operator expertise and is not reliably sensitive for low burdens. Perhaps most concerning, sudden death may be the first and only clinical sign of heartworm infection in cats — a single worm dying and causing acute pulmonary thromboembolism can be fatal. There is no approved adulticide treatment for cats (melarsomine, the drug used in dogs, is toxic to cats), making year-round prevention the only viable strategy for feline heartworm management.

Regular heartworm testing is a cornerstone of preventive care in endemic areas, and understanding the testing options and their limitations helps owners and veterinarians make informed decisions about screening schedules and interpretation of results.

Antigen testing is the primary screening method for heartworm in dogs. These tests detect glycoproteins secreted by adult female Dirofilaria immitis, and modern in-clinic SNAP tests and laboratory-based ELISA tests achieve sensitivity greater than 99 per cent for infections involving at least one mature female worm that is at least six to seven months old. However, antigen tests can produce false negatives in several important scenarios: very early infections (less than five to six months post-exposure, before worms mature and begin producing antigen), low worm burdens (particularly all-male infections, which produce no detectable antigen), and immune-complex formation (where the dog's antibodies bind to and mask the antigen — a phenomenon that can be overcome by heat-treating the serum sample before testing). Because of the six-month lag between infection and antigen detectability, testing a dog immediately after a potential exposure is uninformative — the test must be performed at least six months later to definitively rule out infection from that exposure.

Microfilaria testing complements antigen testing and involves examining a blood sample for the presence of circulating larval heartworms (microfilariae). A modified Knott test or filter concentration test can detect microfilariae with high sensitivity. Approximately 80 per cent of heartworm-positive dogs will also be microfilaremic, but some infected dogs have 'occult' infections — antigen-positive but microfilaria-negative — due to immune-mediated clearance of microfilariae, single-sex infections, or low worm burdens. Combining antigen and microfilaria testing provides the most comprehensive assessment and identifies dogs that are actively serving as reservoirs for mosquito transmission.

The American Heartworm Society recommends annual testing for all dogs, even those on year-round preventive medication. This recommendation exists because no preventive is 100 per cent effective in real-world conditions — owners may miss or delay doses, pets may spit out or vomit oral preventives without the owner's knowledge, and drug resistance has been documented in some Dirofilaria immitis populations in the Mississippi River Valley and Gulf Coast regions of the United States. Annual testing serves as a safety net, catching breakthrough infections early when treatment is safest and most effective, and before significant cardiovascular damage has occurred. For broader guidance on scheduling veterinary visits and screening tests, see our vet visit schedule guide. Puppies should be started on preventive by eight weeks of age and first tested at seven months (to allow time for any infection acquired before starting prevention to become detectable).

Treating heartworm disease in dogs is a complex, expensive, and potentially dangerous process that unfolds over several months — a stark contrast to the simplicity and low cost of prevention. The current gold-standard treatment protocol, recommended by the American Heartworm Society, involves a multi-step approach designed to kill adult worms as safely as possible while minimising the risk of life-threatening pulmonary thromboembolism.

Pre-treatment stabilisation: Before beginning adulticide therapy, dogs with moderate-to-severe disease may require stabilisation with corticosteroids to reduce pulmonary inflammation, diuretics to manage heart failure symptoms, and cage rest to reduce cardiac workload. A thorough pre-treatment workup including chest radiographs, complete blood count, serum biochemistry, and urinalysis helps assess the severity of disease, identify concurrent conditions, and establish baseline values for monitoring during treatment.

The three-injection melarsomine protocol: Melarsomine dihydrochloride (Immiticide or Diroban) is the only FDA-approved adulticide for heartworm treatment in dogs. The recommended protocol involves an initial intramuscular injection deep into the lumbar epaxial muscles, followed by a 30-day rest period, then two additional injections 24 hours apart. This staged approach — known as the 'three-dose protocol' or 'split protocol' — kills adult worms more gradually than simultaneous dosing, reducing the risk of massive pulmonary thromboembolism that can occur when large numbers of worms die simultaneously. Prior to melarsomine treatment, dogs typically receive 30 to 60 days of doxycycline (to weaken the worms by targeting Wolbachia, an essential endosymbiotic bacterium) and monthly preventive medication (to eliminate microfilariae and prevent new infections).

Exercise restriction is arguably the most critical component of the treatment protocol and the most challenging for owners to implement. From the time of diagnosis through at least six to eight weeks after the final melarsomine injection, dogs must be strictly confined — no running, jumping, playing, or vigorous activity. As adult worms die and decompose, fragments are carried into the lungs where they lodge in small pulmonary arterial branches, causing localised inflammation and blood clot formation. In a calm, resting dog, the body can gradually reabsorb these fragments with manageable inflammation. However, increased physical activity dramatically increases blood flow velocity through the lungs, increasing the risk that dead worm fragments will cause massive, life-threatening pulmonary thromboembolism. Owners must understand that a heartworm-positive dog that seems perfectly fine can die suddenly from pulmonary embolism triggered by exercise — the restriction is not optional, it is lifesaving.

Treatment costs vary significantly by region, disease severity, and the dog's size, but typically range from several hundred to several thousand pounds or dollars — compared to the annual cost of preventive medication, which generally ranges from 50 to 150 pounds or dollars depending on the product and the pet's weight. This dramatic cost differential, combined with the pain, risk, and prolonged recovery associated with treatment, underscores the universal veterinary consensus: prevention is infinitely preferable to treatment. For dogs with pre-existing heart disease, the risks of treatment are compounded, and careful veterinary assessment of the risk-benefit ratio is essential before proceeding.

Heartworm prevention is one of the most effective and cost-efficient interventions in veterinary medicine, and the modern array of preventive products offers options to suit virtually every pet, lifestyle, and budget. All heartworm preventives work by killing larval heartworms (L3 and L4 stages) acquired during the previous 30 days, before they can mature and reach the pulmonary arteries. This retroactive mechanism means that even if a mosquito deposits infective larvae on your pet today, the next dose of preventive medication will eliminate those larvae — provided it is given within the effective window.

Monthly oral preventives such as ivermectin-based products (Heartgard Plus), milbemycin oxime (Interceptor Plus, Sentinel), and moxidectin (in combination products) are the most widely prescribed options. Many are formulated as palatable chewable tablets that dogs accept readily, and several combine heartworm prevention with intestinal parasite control, simplifying the preventive care regimen. Monthly topical preventives such as selamectin (Revolution/Stronghold) and moxidectin (Advantage Multi/Advocate) are applied to the skin between the shoulder blades and are particularly useful for dogs that refuse oral medications or for cats (for whom oral dosing can be challenging). Injectable preventives — specifically moxidectin sustained-release (ProHeart 6 and ProHeart 12) — are administered by a veterinarian and provide six or twelve months of continuous protection, eliminating the risk of owner compliance gaps entirely.

The question of seasonal vs year-round prevention has been definitively answered by current veterinary guidelines: year-round prevention is recommended for all dogs and cats in all geographic areas. While mosquito activity is seasonal in temperate climates, the unpredictability of weather patterns, the presence of mosquitoes in heated indoor environments during winter, the increasing geographic spread of heartworm due to transport of infected dogs (particularly through rescue organisations), and the impossibility of predicting exactly when the first and last mosquitoes of the season will be active all argue against seasonal interruption of preventives. Furthermore, many heartworm preventives also control intestinal parasites that are a year-round concern, and any gap in coverage creates a window of vulnerability that could allow a single infected mosquito bite to result in full-blown heartworm disease.

For cat owners who may believe their indoor-only cat is not at risk, research has shown that approximately 25 to 30 per cent of cats diagnosed with heartworm are described by their owners as exclusively indoor cats. Mosquitoes readily enter homes through open doors, windows, and gaps in screens, and a single infected mosquito bite is all it takes. Given that there is no approved treatment for feline heartworm disease and that infection can be fatal, monthly prevention for cats in endemic areas is strongly recommended — particularly for cats living in regions where canine heartworm prevalence is high, as this indicates active mosquito transmission in the area. Remember that your pet's preventive care schedule should include heartworm prevention as a non-negotiable component alongside vaccinations and parasite control.